EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib

Francesca Palandri iD, Filippo Branzanti, Massimiliano Bonifacio iD, Elena M Elli iD, Erika Morsia, Mirko Farina iD, Mario Tiribelli iD, Giulia Benevolo iD, Eloise Beggiato, Bruno Martino, Giovanni Caocci, Novella Pugliese iD und 20 weitere

Cancer · 2025

DOI: 10.1002/cncr.70062 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, 2025. Verfasst von Francesca Palandri und 31 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Pyrazoles. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The response to ruxolitinib after 6 months (RR6) model allows early identification of ruxolitinib‐treated myelofibrosis (MF) patients with poorer overall survival (OS); however, it is less applicable to lower‐risk patients.

Methods

To further explore this, the authors performed a subanalysis of the “RUX‐MF” study (NCT06516406) with an aim to validate the RR6 and to develop a score specific for intermediate‐1 DIPSS/MYSEC‐PM risk patients.

Results

Among the 776 evaluable patients, 34.4%, 47.8%, and 17.8% were at low, intermediate, and high RR6 risk, with 5‐year OS of 64.1%, 51.8%, and 44.5%, respectively ( p < .001). In the 428 intermediate‐1 patients, the RR6 model did not discriminate between intermediate and low‐risk patients (5‐year OS: 74.4% vs. 72.0%, p = .24). The intermediate‐1 specific RR6 (iRR6) model was therefore developed by incorporating new variables: underdosed ruxolitinib with respect to platelet count at one or more time points (hazard ratio [HR], 3.91; p < .001), absence of palpable spleen reduction by ≥50% at 6 months (HR, 1.45; p = .02), and red blood cell transfusion requirement at all time points (HR, 1.85; p = .01). The iRR6 model stratified patients into three risk categories: low (score 0, 20.3%), intermediate (score 1–2, 45.8%), and high‐risk (score >2, 33.9%), with 5‐year OS of 84.8%, 76.4%, and 56.6%, respectively ( p < .0001). The iRR6 model was validated in a cohort of 95 intermediate‐1 risk patients from the Moffitt Cancer Center, yielding stratification into the same three risk categories, with 5‐year OS of 83.3% (low‐risk), 71.7% (intermediate‐risk), and 54.5% (high‐risk) ( p = .01).

Conclusions

The iRR6 model provides a more refined tool for the identification of intermediate‐1 MF patients who may benefit from early therapy shift.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisPyrazolesAgedAged, 80 and overFemaleHumansMaleMiddle AgedNitrilesPyrimidinesRisk AssessmentTreatment Outcome

Stichwörter der Autor:innen

intermediate‐1post‐ET myelofibrosispost‐PV myelofibrosisprimary myelofibrosisruxolitinibsurvival score

Substanzen

NitrilesPyrazolesPyrimidinesruxolitinib

Autor:innen und Institutionen

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
  • Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy.
  • Divisione di Ematologia e Unità Trapianto di Midollo, IRCCS San Gerardo dei Tintori, Monza, Italy.
  • Hematology Unit, Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy.
  • Department of Clinical and Experimental Sciences, Unit of Blood Diseases and Stem Cells Transplantation, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy.

ORCID-Profile: Francesca Palandri, Massimiliano Bonifacio, Elena M Elli, Mirko Farina, Mario Tiribelli, Giulia Benevolo, Novella Pugliese, Elisabetta Abruzzese, Andrea Duminuco, Massimo Breccia, Andrew T Kuykendall

Förderung

  • Ministero della Salute

Zitieren

APA

Palandri, F., Branzanti, F., Bonifacio, M., Elli, E. M., Morsia, E., Farina, M., Tiribelli, M., Benevolo, G., Beggiato, E., Martino, B., Caocci, G., Pugliese, N., Tieghi, A., Crugnola, M., Binotto, G., Cavazzini, F., Abruzzese, E., Isidori, A., Dedola, A., …, & Kuykendall, A. T. (2025). Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib. Cancer. https://doi.org/10.1002/cncr.70062

Vancouver

Palandri F, Branzanti F, Bonifacio M, Elli EM, Morsia E, Farina M, et al. Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib. Cancer. 2025. doi:10.1002/cncr.70062

BibTeX
@article{Palandri2025,
  author = {Palandri, Francesca and Branzanti, Filippo and Bonifacio, Massimiliano and Elli, Elena M and Morsia, Erika and Farina, Mirko and Tiribelli, Mario and Benevolo, Giulia and Beggiato, Eloise and Martino, Bruno and Caocci, Giovanni and Pugliese, Novella and Tieghi, Alessia and Crugnola, Monica and Binotto, Gianni and Cavazzini, Francesco and Abruzzese, Elisabetta and Isidori, Alessandro and Dedola, Alessandra and Scalzulli, Emilia and Duminuco, Andrea and Tosoni, Luca and Strazimiri, Alda and Lemoli, Roberto M and Cilloni, Daniela and Bocchia, Monica and Pane, Fabrizio and Sartor, Chiara and Heidel, Florian H and Breccia, Massimo and Palumbo, Giuseppe A and Kuykendall, Andrew T},
  title = {Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70062}
}
Kostenlos starten →